Headline Expenditure Projections
- Pharmaceuticals: EGP14.34bn (USD2.09bn) in 2013 to EGP15.89bn (USD2.27bn) in 2014; +10.8% in local currency terms and 8.7% in US dollar terms. Forecast revised downwards since Q314 , due deterioration in intellectual property regime.
- Healthcare: EGP84.61bn (USD12.31bn) in 2013 to EGP93.95bn (USD13.42bn) in 2014; +11.0% in local currency terms and 9.0% in US dollar terms. Forecast broadly in line with the previous quarter.
Risk/Reward Rating: Despite the persistent political instability and the associated economic under-performance, Egypt remains a moderately attractive commercial opportunity for multinational pharmaceutical companies. In the Q314 Pharmaceutical Risk/Reward Ratings (RRRs) Egypt's score of 45.5 out of 100 is slightly higher than the Q214 score of 43.1. This has improved its status in the Middle East and Africa region, making it the 11 th
most attractive market (up from 12 th
in the previous quarter).
Key Trends And Developments
Egypt was assigned 'Watch List' status In the Pharmaceutical Research and Manufacturers of America (PhRMA)'s 2014 Special 301 submission, due to the association's concerns over insufficient intellectual property (IP) rights protection and enforcement.
A three-month deadline given by Egypt's Office of Patents to a US-based pharmaceutical company, presumed to be Gilead Sciences, that supplied drugs for the treatment of hepatitis C ended on May 8 2014. The...
The Egypt Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.
BMI's Egypt Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Egyptian pharmaceutical and healthcare industry.Key Benefits
CoverageBMI Industry View & Industry SWOT
- Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Egypt to test other views - a key input for successful budgeting and strategic business planning in the Egyptian pharmaceutical and healthcare market.
- Target business opportunities and risks in the Egyptian pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Egypt.
- Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's political, economic and business environment SWOTS, it gives a complete overview of market climate.Market Summary
Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.Regulatory Regime
Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.BMI Industry Forecasts
Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per `000 population), doctors (per `000 population), birth and mortality rate (per `000 population)
Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)
Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)
Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)
OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)
Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)
Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.Competitive Landscape
The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.Company Profiles
Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI's industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.
The landslide victory by Abdel Fattah al-Sisi in the presidential election in Egypt increases the attractiveness of the country ' s pharmaceutical market, which has been deteriorating for the past few years. Key challenges facing multinational companies include a restrictive medicine pricing regime, a lack of regulatory data protection and poor patent enforcement. Domestic companies are meanwhile impaired by a weakened currency, which restricts their ability to import raw materials for manufacturing pharmaceuticals.